Research and Development

Merck KGaA has completed patient enrollment for a phase III global trial of its first-in-class integrin inhibitor in a rare …

UK and India-based e-Therapeutics has appointed Dr Daniel Elger as chief financial officer. He joins the drug discovery company from …

The European Medicines Agency has nominated Italy’s Guido Rasi to be its next head, after a protracted and messy search. …

Medical and pharma groups have blamed European Union red tape for the decline in the UK as a location for …

Lilly has appointed Andrew Hotchkiss president of its operations in Australia, Canada and Europe. Andrew has been with the company …

Japanese pharma company Daiichi Sankyo is expanding its European operations, creating a new oncology business unit. But outlining its plans …

Merck Serono has struck a deal with biotech firm Affectis Pharmaceuticals to develop oral neurodegeneration compounds. The companies will commercialise …

Dr Richard Barker has been at the helm of the UK pharma industry for over six years, but is now …

Following the success of the recent pharmacovigilance webinars delivered, Wainwright Associates are offering a webinar on An Introduction to Scientific …

Oxford, UK-based gene therapy company Oxford BioMedica has appointed Dr Alex Lewis as director of corporate activities and strategy, and …

In an industry first Pfizer is to use mobile phone and web-based technology to collect study data for pharma’s first …

Roche has signed a deal to develop diagnostic tests for products in Merck’s oncology pipeline, in a bid to make …

One Nucleus is a new organisation formed from the merger of two of England’s regional networks – ERBI (Eastern Region …

Merck & Co is to submit its oral investigational cancer drug ridaforolimus to European and US regulators later this year …

Studies of Merck Serono’s Erbitux in rectal cancer have shown improved overall survival, a gold standard measure in oncology trials. …